Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

B. Lowenberg*, T. Pabst, J. Maertens, P. Gradowska, B.J. Biemond, O. Spertini, E. Vellenga, L. Griskevicius, L.W. Tick, M. Jongen-Lavrencic, M.V. Kooy, M.C. Vekemans, W.J.F.M. van der Velden, B. Beverloo, L. Michaux, C. Graux, D. Deeren, O. de Weerdt, J.W.J. van Esser, M. BargetziS.K. Klein, A. Gadisseur, P.E. Westerweel, H. Veelken, M. Gregor, T. Silzle, D. Van Lammeren-Venema, I. Moors, D.A. Breems, M. Hoogendoorn, M.C.J.C. Legdeur, T. Fischer, J. Kuball, J. Cornelissen, K. Porkka, G. Juliusson, P. Meyer, M. Hoglund, B.T. Gjertsen, J.J.W.M. Janssen, G. Huls, J. Passweg, J. Cloos, P.J.M. Valk, C.H.M.J. van Elssen, M.G. Manz, Y. Floisand, G.J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) , Swiss Group for Clinical Cancer Research (SAKK)

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1110-1121
Number of pages12
JournalBlood advances
Volume5
Issue number4
DOIs
Publication statusPublished - 23 Feb 2021

Keywords

  • ACUTE MYELOID-LEUKEMIA
  • HIGH-DOSE LENALIDOMIDE
  • AZACITIDINE PLUS LENALIDOMIDE
  • MINIMAL RESIDUAL DISEASE
  • SEQUENTIAL AZACITIDINE
  • ELDERLY-PATIENTS
  • COMBINATION
  • CYTARABINE

Cite this